



Universiteit
Leiden
The Netherlands

Apo-calypse now? Apolipoprotein profiling to reduce residual cardiovascular disease

Reijnders, E.

Citation

Reijnders, E. (2025, October 30). *Apo-calypse now?: Apolipoprotein profiling to reduce residual cardiovascular disease.*


Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from:

Note: To cite this publication please use the final published version (if applicable).

CHAPTER 7



Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests

**E. Reijnders^{1,a}, M. Szarek^{2,3,a}, J.W. Jukema⁴, D.L. Bhatt⁵, V.A. Bittner⁶, R. Diaz⁷, S. Fazio⁸,
G. Garon⁹, S.G. Goodman¹⁰, R.A. Harrington¹¹, L.R. Ruhaak¹, M. Schwertfeger¹², S. Tsimikas¹³,
H.D. White¹⁴, G. Steg¹⁵, C.M. Cobbaert^{1,a}, G.G. Schwartz^{2,a}, for the ODYSSEY OUTCOMES
Investigators^b**

a. These authors contributed equally.

b. The ODYSSEY OUTCOMES Committee members, investigators, and contributors are listed
in the online-only Data Supplement.

1. Department of Clinical Chemistry and Laboratory Medicine,
Leiden University Medical Centre, Leiden, The Netherlands
2. Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA
3. CPC Clinical Research, Aurora, CO, USA and State University of New York, Downstate
Health Sciences University, Brooklyn, NY, USA
4. Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands and
Netherlands Heart Institute, Utrecht, The Netherlands
5. Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, NY, USA
6. Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA
7. Estudios Cardiológicos Latino América, Instituto Cardiovascular de Rosario, Rosario, Argentina
8. Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA
9. Sanofi, Ontario, Canada
10. Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada and
St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
11. Stanford Center for Clinical Research, Department of Medicine, Stanford University,
Stanford, CA, USA
12. Roche Diagnostics International AG, Zug, Switzerland
13. Sulpizio Cardiovascular Center, Division of Cardiovascular Medicine,
University of California San Diego, La Jolla, CA, USA
14. Green Lane Cardiovascular Research Unit, Te Whatu Ora – Health New Zealand,
Te Toka Tumai, and University of Auckland, Auckland, New Zealand
15. Université Paris-Cité, INSERM-UMR1148, F-75018, Assistance Publique-Hôpitaux de
Paris, Hôpital Bichat, FACT (French Alliance for Cardiovascular Trials), and
Institut Universitaire de France, Paris, France

CLINICAL PERSPECTIVE

What Is New?

- In patients with recent ACS, we compared 2 immunoassay-based tests that report mass and molar lipoprotein(a) concentration with a mass spectrometry-based test that reports molar apolipoprotein(a) concentration in relation to major adverse cardiovascular event (MACE) risk and reduction of this risk with the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor alirocumab.
- Estimated cumulative incidence of MACE within the placebo group increased with higher lipoprotein(a) percentiles and differed by $\leq 0.4\%$ among tests.
- Across percentiles of lipoprotein(a) as determined by the 3 tests, the, estimated treatment hazard ratios for MACE (alirocumab:placebo) differed by ≤ 0.07 among tests, with nominally less relative risk reduction by alirocumab at lower percentiles.

What Are the Clinical Implications?

- At a cohort level, the evaluated mass and molar lipoprotein(a) immunoassays were similarly prognostic for risk of MACE and predictive of MACE reduction with alirocumab.
- In terms of choosing a commercially available lipoprotein(a) immunoassay for individual prognosis, both of the evaluated tests provide comparable risk assessment.

INTRODUCTION

A relationship between the circulating concentration of lipoprotein(a), a genetically determined low-density lipoprotein particle, and the risk of cardiovascular events has been established in epidemiological studies,¹ in Mendelian randomization analyses,^{2, 3} and in the setting of cardiovascular outcomes trials.⁴⁻⁶ Furthermore, a recent European Atherosclerosis Society consensus statement summarized the cumulative evidence supporting a causal continuous association between lipoprotein(a) concentration and cardiovascular events, substantiating clinical guideline recommendations and the inclusion of lipoprotein(a) in estimates of global cardiovascular risk.⁷

Initial reports relating lipoprotein(a) to cardiovascular events typically used immunoassay based measurements of mass (i.e., in units of milligrams per deciliter). More recently, commercial lipoprotein(a) tests have been developed with standardization against the internationally endorsed ELISA based Reference Measurement Procedure and World Health Organization/International Federation of Clinical Chemistry and Laboratory Medicine SRM2B reference material, expressing lipoprotein(a) concentration in molar units (nanomoles per liter).⁸ Previous clinical studies and guidelines have variably defined risk in terms of immunoassay-based mass⁴ or molar⁵ concentration of lipoprotein(a). In addition, eligibility criteria for ongoing trials of therapeutics that substantially decrease lipoprotein(a) levels have variably set minimum qualifying concentrations in mass⁹ or molar¹⁰ units. The potential transition to molar concentration being the preferred unit of measurement is further complicated by the fact that there is no consistent conversion factor between mass and molar scales because of differing lipoprotein(a) isoform dependency of each immunoassay-based analytic method.^{7, 11} Although commercially available immunoassays that measure lipoprotein(a) in mass or molar units have been compared in patients unselected for cardiovascular risk,¹² they have not been compared in terms of prognosis for cardiovascular events in a cohort of high-risk patients. A third, investigational analytic approach to lipoprotein(a) concentration utilizing mass spectrometry (MS) has the potential to improve measurement because it is unaffected by apolipoprotein(a) (Apo(a)) isoform (number of kringle IV type 2 repeats) and has an extended measurement range.¹³ However, no information exists on the prognostic information provided by this assay method.

The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the convertase subtilisin/kexin type 9 inhibitor alirocumab with placebo in patients with recent ACS. In previous reports from the trial, we found that lipoprotein(a) concentration measured with a commercial immunoassay-based mass test (IA-mass) was prognostic for future major adverse cardiovascular events (MACE) and total cardiovascular events and predictive of the effect of alirocumab to reduce the risk of these events.^{4, 14} In light of the methodologic issues pertaining to lipoprotein(a) assessment, we measured its concentration in trial participants using three methods: the aforementioned IA-mass test, a

commercial immunoassay-based molar test (IA-molar), and a semiautomated laboratory-developed multiplex MS-based test. The aims of this study were to evaluate the degree of correspondence among the three measurement methods in a well-characterized clinical trial population and compare the prognostic and predictive information for cardiovascular events provided by each test.

METHODS

Requests from qualified investigators for data from the ODYSSEY OUTCOMES trial will be considered by its executive steering committee and the sponsor and should be submitted to odysseyoutcomesesc@gmail.com.

Study Population

The design,¹⁵ primary results,¹⁶ total events results,¹⁷ and lipoprotein(a) mass concentration findings^{4,14,18} from the ODYSSEY OUTCOMES trial have been published. A total of 18 924 patients from 1315 sites in 57 countries were randomized in a 1:1 ratio to receive 75 mg of alirocumab (increased to 150 mg for those who did not achieve a low-density lipoprotein cholesterol [LDL-C] level of <50 mg/dL [1.29 mmol/L]) or matching placebo subcutaneously every 2 weeks. Key inclusion criteria included age ≥40 years, hospitalization with ACS (myocardial infarction or unstable angina) 1 to 12 months before randomization, an LDL-C level ≥70 mg/dL (1.81 mmol/L), a non-high-density lipoprotein cholesterol level ≥100 mg/dL (2.59 mmol/L), or apolipoprotein B ≥80 mg/dL during stable treatment with 40 to 80 mg of atorvastatin daily, 20 to 40 mg of rosuvastatin daily, or the maximum tolerated dose of either statin. The trial was approved by the institutional review board of each site, and all patients provided informed consent.

Participants without available baseline results from all three lipoprotein(a) tests were excluded from the current analyses, including those recruited from countries or sites where additional exploratory laboratory testing was not permitted or not possible. In addition, results from month-4 samples from this cohort were included in the analyses if they were available.

Outcomes

The primary efficacy outcome of the study and of the current analysis was time to first occurrence of a MACE, consisting of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. We also analyzed all cardiovascular outcomes observed during the trial, including cardiovascular death and total (first and subsequent) nonfatal cardiovascular events. The latter category included nonfatal primary outcome events, hemorrhagic stroke, hospitalization for heart failure, ischemia-driven coronary revascularization, major peripheral artery disease (PAD) events (critical limb ischemia, lower extremity revascularization procedures, or amputation for ischemia), venous thromboembolism

(VTE), deep vein thrombosis and pulmonary embolism. Noncardiovascular deaths were also recorded during follow-up but were not included as events in any analyses. All events included in the analyses except PAD events and VTE were adjudicated by an independent committee blinded to treatment assignment; PAD events and VTE were reported by investigators blinded to treatment assignment on a specific case report form.

Measurement of Lipoprotein(a)

Lipoprotein(a) measurement by IA-mass was performed as part of the lipid central laboratory assessments for all randomized patients. Samples frozen at -20°C were shipped from study sites to Covance Laboratories, where they were stored at -70°C until measurement on a Siemens BNII analyzer using an immunonephelometric assay (Siemens N Latex) with rabbit polyclonal anti-lipoprotein(a) detection antibody with interassay coefficient of variation of 3.1% to 4.8%, depending on lipoprotein(a) levels (Siemens, Healthcare Diagnostics).

Molar concentrations of lipoprotein(a) were assessed by an immunoassay (IA-molar) and by MS in serum samples received on dry ice and stored at -80°C at Leiden University Medical Center, performed in a single laboratory as part of a prespecified biomarker substudy. Samples were thawed and divided into 2 aliquots in batches, of which the immunoassay aliquot was stored at 4°C overnight and analyses were performed daily on freshly thawed samples. The MS aliquot was stored at -80°C for up to 1 year before analysis on freshly thawed samples.

IA-molar measurements of lipoprotein(a) were assessed by a Roche Cobas C 502 analyzer using an immunoturbidimetric assay (Roche Tina-Quant Lipoprotein(a) Gen.2) with rabbit polyclonal anti-lipoprotein(a) detection (Roche Diagnostics). Bilevel internal quality control samples were measured at the start and end of every analysis day. Three high-lipoprotein(a) internal quality control sample lots resulted in mean values (SD) of 106.6 nmol/L (2.8), 112.5 nmol/L (3.6), and 111.2 nmol/L (3.0), with an overall interassay coefficient of variation of 2.9%.

Apo(a) in lipoprotein(a) was measured with a higher-order¹⁹ semiautomated laboratory-developed multiplex MS test (1290 Infinity II ultra-high-performance liquid chromatography instrument coupled to 6495 triple quadrupole-MS by Agilent Technologies).²⁰ Sample preanalysis was performed on a 96-channel Agilent BRAVO automated liquid handling platform. Proteins in serum samples were denatured, reduced, alkylated, and, after tryptic digestion, measured by MS as published previously, for 6 apolipoproteins.²⁰ For Apo(a) quantification, proteotypic peptides LFLEPTQADIALLK (in the peptidase domain) and GISSTVTGR (in the kringle 4 type 9 domain) were measured. Apo(a) was quantified with 5 value-assigned native serum calibrators, guaranteeing metrologic traceability to SRM2B and the World Health Organization/International Federation of Clinical Chemistry and Laboratory Medicine reference measurement system.^{8, 21} Bilevel native

serum internal quality control samples were measured in triplicate and evaluated by Levey-Jennings plots with adjusted Westgard rules to fit a multiplex test to assess assay performance.²² ²³ One high-lipoprotein(a) internal quality control sample lot resulted in a mean value (SD) of 89.6 nmol/L (2.7) and an interassay coefficient of variation of 3.0%. This test is validated according to clinical and laboratory standards institute protocols. Additional technical details of the tests are provided in Table S1. IA-mass relies on serial dilution of a single calibrator; IA-molar and MS use 5 independent calibrators. The immunoassay tests use polyclonal Apo(a)-directed antibodies that are reported to detect the repeating KIV2 of Apo(a), making their results Apo(a) isoform dependent.²⁴ This effect is more pronounced when combined with a single serially diluted calibrator, as in the case of the IA-mass test.^{25, 26} The MS test is Apo(a) isoform independent by design as the selected peptides are KIV2 independent. Both immunoassay tests require dilution steps (by design to calibrators with nonmatching Apo(a) isoforms) if measurements exceed the upper limit of the measuring range, whereas this is less frequently required for the MS test because of its relatively extended measurement range.

Statistical Analysis

For statistical modeling purposes, an Apo(a) concentration below the corresponding lower limit of quantification (4.0 mg/dL for IA-mass, 7.0 nmol/L for IA-molar, and 3.8 nmol/L for MS) was set to the midpoint between 0 and the respective lower limit of quantification (ie, 2.0 mg/dL for IA-mass, 3.5 nmol/L for IA-molar, and 1.9 nmol/L for MS-molar). Continuous variables are described by median (quartile 1 and quartile 3); categorical variables are presented as counts and percentages. Comparisons of demographic and baseline characteristics between patients included in or excluded from the analysis cohort were determined by Wilcoxon or χ^2 tests. Relationships between baseline lipoprotein(a) and LDL-C were estimated by Spearman correlations. Distributions of lipoprotein(a) are described by treatment group at baseline, along with the absolute and percentage change from baseline to month 4 (122 $\pm$ 28 days) after randomization. The first value was analyzed if a participant had multiple values within the time window.

To facilitate comparisons among measurements of lipoprotein(a) using different units of concentration, baseline values from each analysis method were converted into percentiles. With the MS test selected as the comparison method to which the other 2 assessments were compared, the difference between baseline IA-mass or IA-molar percentile and MS percentile was plotted as a function of MS percentile. In this fashion, positive values indicate overestimation with the comparator method versus MS and negative values indicate underestimation. Because IA-molar and MS share units of measurement, a Bland-Altman plot of lipoprotein(a) concentrations from these tests was also generated, and equivalence was tested by Deming regression using jackknife estimates for standard errors to calculate 95% CIs for the slope and y intercept.²⁷

Within the placebo group, cumulative incidence of a first MACE and total cardiovascular events per 100 patients through 4 years by continuous baseline IA-mass, IA-molar, and MS concentration percentiles were estimated by natural cubic splines and associated 95% CIs from Poisson regression models. The models included log follow-up time as an offset and baseline LDL-C as a covariate; sensitivity analyses included additional covariates that are associated with risk or lipoprotein(a) concentrations (i.e., age, sex, race, body mass index, history of diabetes, and baseline triglycerides). Knots were specified at the 25th, 50th, and 75th percentiles, and Wald tests were used to assess significance of the spline effects. To quantify the incremental value of each test for a MACE prognosis after accounting for LDL-C, absolute and relative integrated discrimination improvement was calculated for IA-mass, IA-molar, and MS natural cubic splines, both for percentiles and in their original units.²⁸

Treatment hazard ratios (HRs) by percentiles of the baseline lipoprotein(a) concentrations were assessed by natural cubic splines and associated 95% CIs from proportional hazards models for a first MACE and, for total cardiovascular events, marginal proportional hazards models that allow for a given patient to have multiple events. A robust sandwich variance estimate for the estimated standard error of the log HR was applied to account for the dependence of event times within individual patients. Model covariates, locations of knots, and testing for significance of spline effects followed the specifications for the Poisson regression models described previously.

To further illustrate the relationships between baseline lipoprotein(a) and absolute risk of a first MACE and total cardiovascular events, rates per 100 patient-years of follow-up with corresponding 95% CIs within each treatment group and alirocumab treatment absolute rate reductions with 95% CIs were estimated by baseline lipoprotein(a) quartile of each analytical method by Poisson regression models. Log follow-up time was included in the models as an offset. To assess patterns of risk within the placebo group and heterogeneity in the treatment effects, P values were computed for linear trend in the estimated placebo rates and absolute rate reductions across quartiles.

P values <0.05 from two-sided tests were considered statistically significant. All analyses were conducted according to intention-to-treat, including all patients and events from randomization to the common study end date (November 11, 2017). Analyses were conducted using SAS version 9.4 (SAS Institute).

RESULTS

Participant Characteristics and Relationships Between Baseline Lipoprotein(a) Assessments

A total of 11 970 participants had baseline IA-mass, IA-molar, and MS lipoprotein(a) assessments; of these patients, 11 167 (93%) also had month-4 assessments. Patients from Canada or the United States were overrepresented among the participants included in the analysis cohort, whereas participants

from Central and Eastern Europe were overrepresented among the 6954 excluded participants (Table S2). Relative to the excluded participants, included participants had higher lipoprotein(a) IA-mass and apolipoprotein B concentrations and were less likely to have a history of heart failure. Of note, nearly 90% of participants had been receiving high-intensity statin treatment with 40–80 mg of atorvastatin or 20–40 mg of rosuvastatin at the time of randomization. Characteristics of those included in the analysis cohort are summarized by treatment assignment in Table 1.

Table 1: Demographics and Baseline Clinical Characteristics of the Analysis Cohort by Treatment Assignment

Characteristic	Alirocumab (n=5977)	Placebo (n=5993)
Age, y	58 (51, 65)	58 (52, 65)
Female sex	1421 (23.8)	1438 (24.0)
Body mass index, kg/m ²	28.0 (25.4, 31.2)	28.0 (25.2, 31.2)
Systolic blood pressure, mmHg	127 (118, 138)	126 (116, 138)
Revascularization for index ACS	4342 (72.6)	4423 (73.8)
Race		
White	4786 (80.1)	4836 (80.7)
Asian	721 (12.1)	721 (12.0)
Black	168 (2.8)	157 (2.6)
Other	302 (5.1)	279 (4.7)
Region of enrollment		
Central and Eastern Europe	1159 (19.4)	1159 (19.3)
Western Europe	1406 (23.5)	1414 (23.6)
Canada or United States	1405 (23.5)	1409 (23.5)
Latin America	799 (13.4)	795 (13.3)
Asia	690 (11.5)	691 (11.5)
Rest of World	518 (8.7)	525 (8.8)
Baseline laboratory data		
Lipoprotein (a) immunoassay-based mass concentration, mg/dL	21.1 (6.9, 58.7)	22.4 (6.8, 61.1)
Lipoprotein (a) immunoassay-based molar concentration, nmol/L	44.4 (13.3, 150.6)	45.4 (13.1, 157.3)
Lipoprotein (a) mass spectrometry-based concentration, nmol/L	41.1 (14.4, 139.9)	43.0 (14.3, 146.3)
Low-density lipoprotein cholesterol, mg/dL	86.5 (72.6, 103.9)	86.5 (73.0, 105.0)
Corrected Low-density lipoprotein cholesterol, mg/dL	75.4 (60.7, 94.2)	75.2 (60.4, 93.5)
Apolipoprotein B, mg/dL	80.0 (69.0, 93.0)	80.0 (69.0, 94.0)
Non-high-density lipoprotein cholesterol, mg/dL	115.0 (98.8, 137.0)	115.8 (99.2, 138.0)
High-density lipoprotein cholesterol, mg/dL	42.1 (36.0, 50.0)	42.1 (36.0, 49.8)
Triglycerides, mg/dL	130.1 (94.7, 182.0)	131.9 (95.1, 185.4)
High Sensitivity C-reactive Protein, mg/dL	0.17 (0.08, 0.37)	0.17 (0.08, 0.40)
Estimated glomerular filtration rate, mL/min/1.73 m ²	77.9 (67.2, 90.1)	78.2 (67.4, 90.5)
Hemoglobin A1c, %	5.8 (5.5, 6.3)	5.8 (5.5, 6.4)
Medical history before index ACS		
Hypertension	3807 (63.7)	3739 (62.4)
Diabetes mellitus	1746 (29.2)	1790 (29.9)
Current tobacco smoker	1436 (24.0)	1457 (24.3)
Myocardial infarction	1136 (19.0)	1185 (19.8)
Percutaneous coronary intervention	1126 (18.8)	1128 (18.8)

Characteristic	Alirocumab (n=5977)	Placebo (n=5993)
Coronary artery bypass grafting	374 (6.3)	356 (5.9)
Stroke	187 (3.1)	188 (3.1)
Peripheral artery disease	240 (4.0)	251 (4.2)
Congestive heart failure	544 (9.1)	567 (9.5)
Chronic obstructive pulmonary disease	263 (4.4)	272 (4.5)
Malignancy	207 (3.5)	206 (3.4)
Time from index ACS to randomization, months	2.7 (1.7, 4.5)	2.7 (1.7, 4.5)
Background lipid lowering therapy at randomization		
High-dose atorvastatin/rosuvastatin	5287 (88.5)	5360 (89.4)
Low- or moderate-dose atorvastatin/rosuvastatin	475 (7.9)	425 (7.1)
No statin or other lipid-lowering therapy	75 (1.3)	78 (1.3)
Only lipid-lowering therapy other than statin	127 (2.1)	107 (1.8)
Other statin	13 (0.2)	23 (0.4)

Values are medians (interquartile range) for continuous variables and n (%) for categorical variables.

Baseline lipoprotein(a) IA-mass, IA-molar, and MS concentrations were highly correlated, with the strongest correlation between IA-molar and MS ($r=0.990$) and nominally weaker correlations between IA-mass and MS ($r=0.967$) and IA-mass and IA-molar ($r=0.972$; Table S3). All three measures had modest correlations with LDL-C. As shown in Figure S1, the distributions of lipoprotein(a) IA-mass, IA-molar, and MS concentrations at baseline in the overall analysis cohort were right-skewed. The proportions of patients with values below the lower limit of quantification at baseline were 15.7%, 13.6%, and 5.6% for IA-mass, IA-molar, and MS concentrations, respectively.

The ratios of baseline IA-molar to IA-mass and MS to IA-mass were not constant across the range of lipoprotein(a) concentration (Figure S2). Examination of the baseline molar:mass ratios across quartiles also indicated variability across the distributions (Table 2), ranging from ≈ 1.8 nmol/10 mg in the first quartile to ≈ 2.5 nmol/10 mg in the fourth quartile. Thus, a fixed molar/mass concentration ratio was deemed inappropriate for comparison of tests with mass versus molar concentration readouts. Instead, this finding supported the use of ordinal ranking in percentiles for comparative modeling. Plots of baseline MS percentile versus the difference in percentile between IA-mass and MS or IA-molar and MS revealed generally greater differences between the IA-mass and MS percentiles (Figure 1A) than between the IA-molar and MS percentiles (Figure 1B). Overall, IA-mass overestimated or underestimated concentration by ≥ 20 percentiles on the lipoprotein(a) distributions compared with MS in 1.5% of patients (overestimation 0.4% and underestimation 1.1%), whereas IA-molar concentration overestimated or underestimated concentration by ≥ 20 percentiles on the lipoprotein(a) distributions relative to MS in 0.5% of patients (overestimation 0.1% and underestimation 0.4%). Using a threshold of ± 10 percentiles, IA-mass overestimated or underestimated lipoprotein(a) concentration by MS in 11.9% of patients, while IA-molar overestimated or underestimated concentration by MS in 2.2% of patients.

Table 2: Baseline, Month 4, and Absolute Change From Baseline to Month 4 in Lipoprotein(A) Concentrations By Treatment Group Overall and by Biomarker-Specific Baseline Quartile

	Baseline		Month 4		Absolute change baseline to month 4		Percent change baseline to month 4	
	Alirocumab	Placebo	Alirocumab	Placebo	Alirocumab	Placebo	Alirocumab	Placebo
IA-mass concentration, mg/dL								
Overall	n=5977 21.1 (6.9, 58.7)	n=5993 22.4 (6.8, 61.1)	n=5587 13.3 (2.0, 46.3)	n=5580 20.7 (6.3, 59.5)	n=5587 -5.1 (-13.4, 0)	n=5580 0 (-4.8, 2.8)	n=5587 -23.6 (-46.5, 0)	n=5580 0 (-16.9, 11.8)
Quartile 1 (<6.9 mg/dL)	n=1486 2.0 (2.0, 4.9)	n=1503 2.0 (2.0, 4.9)	n=1393 2.0 (2.0, 2.0)	n=1401 2.0 (2.0, 5.1)	n=1393 0 (-2.0, 0)	n=1401 0 (0, 0.2)	n=1393 0 (-30.8, 0)	n=1401 0 (0, 4.1)
Quartile 2 (6.9 to <21.8 mg/dL)	n=1543 12.6 (9.5, 16.4)	n=1446 12.7 (9.6, 16.5)	n=1441 6.7 (4.5, 10.8)	n=1360 11.9 (8.0, 16.8)	n=1441 -5.2 (-8.0, -2.5)	n=1360 -0.5 (-3.0, 2.3)	n=1441 -41.7 (-65.9, -22.4)	n=1360 -4.1 (-25.3, 18.5)
Quartile 3 (21.8 to <60.0 mg/dL)	n=1491 38.3 (29.3, 48.8)	n=1508 38.6 (28.8, 48.5)	n=1390 28.0 (18.6, 40.2)	n=1389 37.8 (26.3, 50.0)	n=1390 -9.8 (-16.0, -3.3)	n=1389 -1.0 (-7.1, 5.5)	n=1390 -25.9 (-43.6, -8.7)	n=1389 -3.0 (-19.5, 14.8)
Quartile 4 (≥ 60.0 mg/dL)	n=1457 90.1 (72.9, 117.0)	n=1536 92.1 (73.6, 120.0)	n=1363 71.7 (55.6, 96.1)	1430 87.9 (69.0, 118.0)	n=1363 -20.0 (-33.7, -8.1)	n=1430 -5.0 (-17.2, 7.8)	n=1363 -22.0 (-33.8, -9.5)	n=1430 -5.2 (-17.7, 8.1)
IA-molar concentration, nmol/L								
Overall	n=5977 44.4 (13.3, 150.6)	n=5993 45.4 (13.1, 157.3)	n=5587 24.4 (7.1, 119.4)	n=5580 42.3 (11.9, 151.4)	n=5587 -11.9 (-32.0, -2.0)	n=5580 -0.1 (-9.4, 4.2)	n=5587 -26.8 (-49.0, -5.0)	n=5580 -0.1 (-6.0, 8.8)
Quartile 1 (<13.2 nmol/L)	n=1484 3.5 (3.5, 9.6)	n=1505 3.5 (3.5, 9.6)	n=1389 3.5 (3.5, 3.5)	n=1408 3.5 (3.5, 9.6)	n=1389 0 (-4.3, 0)	n=1408 0 (0, 0.2)	n=1389 0 (-53.9, 0)	n=1408 0 (0, 2.1)
Quartile 2 (13.2 to <45.0 nmol/L)	n=1520 23.2 (17.4, 32.5)	n=1475 25.0 (18.0, 33.1)	n=1421 12.1 (8.5, 18.2)	n=1378 23.4 (15.6, 32.6)	n=1421 -10.8 (-16.3, -5.8)	n=1378 -1.4 (-5.6, 3.3)	n=1421 -46.3 (-64.8, -28.0)	n=1378 -5.9 (-24.1, 14.0)
Quartile 3 (45.0 to <153.8 nmol/L)	n=1519 85.5 (60.2, 123.1)	n=1471 87.0 (61.1, 121.1)	n=1425 60.3 (37.6, 94.8)	n=1356 82.7 (56.5, 119.7)	n=1425 -24.1 (-36.7, -11.2)	n=1356 -3.5 (-15.5, 9.7)	n=1425 -29.0 (-45.5, -13.1)	n=1356 -4.4 (-18.4, 11.9)
Quartile 4 (≥ 153.8 nmol/L)	n=1454 227.5 (186.0, 295.5)	n=1542 225.3 (186.8, 301.5)	n=1352 184.5 (146.1, 235.2)	n=1438 217.5 (176.2, 286.3)	n=1352 -49.5 (-81.3, -22.2)	n=1438 -9.1 (-35.0, 14.3)	n=1352 -21.6 (-31.5, -10.1)	n=1438 -4.1 (-14.3, 5.6)

	Baseline		Month 4		Absolute change baseline to month 4		Percent change baseline to month 4	
	Alirocumab	Placebo	Alirocumab	Placebo	Alirocumab	Placebo	Alirocumab	Placebo
MS concentration, nmol/L								
Overall	n=5977 41.1 (14.4, 139.9)	n=5993 43.0 (4.3, 146.3)	n=5587 25.8 (8.3, 110.3)	n=5580 39.4 (13.1, 138.5)	n=5587 -10.4 (-28.2, -2.7)	n=5580 -1.2 (-9.4, 3.8)	n=5587 -27.4 (-46.5, -9.5)	n=5580 -3.4 (-18.5, 10.5)
Quartile 1 (<14.3 nmol/L)	n=1481 7.0 (3.9, 10.5)	n=1495 7.0 (3.9, 10.6)	n=1385 4.3 (1.9, 7.0)	n=1400 6.7 (2.9, 10.7)	n=1385 -2.0 (-4.4, 0)	n=1400 0 (-1.9, 1.8)	n=1385 -25.9 (-56.2, 0)	n=1400 0 (-20.4, 22.8)
Quartile 2 (14.3 to <42.2 nmol/L)	n=1534 23.7 (18.5, 31.2)	n=1475 24.5 (18.6, 31.7)	n=1434 14.2 (10.0, 19.6)	n=1379 23.1 (17.0, 31.2)	n=1434 -9.6 (-14.1, -5.0)	n=1379 -1.3 (-5.3, 3.4)	n=1434 -40.6 (-55.8, -22.3)	n=1379 -5.6 (-23.1, 12.7)
Quartile 3 (42.2 to <143.1 nmol/L)	n=1511 80.6 (57.5, 112.8)	n=1481 81.3 (57.3, 111.1)	n=1415 57.2 (36.7, 89.5)	n=1370 77.3 (52.5, 108.8)	n=1415 -21.1 (-32.5, -9.6)	n=1370 -4.3 (-14.2, 7.4)	n=1415 -27.3 (-42.4, -11.9)	n=1370 -5.1 (-17.9, 8.7)
Quartile 4 (≥ 143.1 nmol/L)	n=1451 219.1 (173.6, 284.4)	n=1542 218.1 (175.8, 292.3)	n=1353 176.6 (138.1, 234.3)	n=1431 211.0 (164.5, 279.2)	n=1353 -45.6 (-72.6, -18.0)	n=1431 -10.4 (-36.0, 13.0)	n=1353 -20.4 (-30.7, -8.9)	n=1431 -4.6 (-14.9, 5.6)

IA indicates immunoassay; and MS, mass spectrometry. Values are medians (interquartile range).




Figure 1: Baseline lipoprotein(a) MS concentration percentile vs difference in IA-mass and MS concentration percentiles and difference in IA-molar and MS concentration percentiles. Scatterplots of baseline lipoprotein(a) mass spectrometry (MS) concentration percentile vs difference in immunoassay-based mass test (IA-mass; **A**) and MS concentration percentiles and MS concentration percentile vs difference in immunoassay-based molar test (IA-molar; **B**) and MS concentration percentiles. IA-mass overestimated and underestimated concentration by ≥ 20 (≥ 10) percentiles compared with MS in 0.4% (3.9%) and 1.1% (8.0%) of patients, respectively. IA-molar overestimated and underestimated concentration by ≥ 20 (≥ 10) percentiles relative to MS in 0.1% (0.2%) and 0.4% (2.0%) of patients, respectively.

A Bland-Altman analysis of baseline IA-molar versus MS concentrations in their original molar units is presented in Figure S3, with positive differences indicating patients with higher IA-molar concentrations and negative differences indicating patients with higher MS concentrations. The overall bias was small (3.8 nmol/L), but 95% limits of agreement were relatively wide (−50.7 to 58.3 nmol/L). Among 5993 patients in the placebo group, there were 108 (1.8%) above, 5734 (95.7%) within, and 151 (2.5%) below the 95% limits of agreement. In a Deming regression analysis, the 95% CI for the estimated slope excluded 1 and the 95% CI for γ intercept excluded 0, indicating that the 2 testing methods are not equivalent (Figure S4). Results were essentially identical from sensitivity analyses excluding observations below the lower limit of quantification on the MS test or on either test.

Baseline Lipoprotein(a), Risk of First MACE and Total Cardiovascular Events in the Placebo Group, and Effects of Alirocumab

Patients in the analysis cohort were followed for cardiovascular events for a median of 2.9 years (interquartile range, 2.4–3.5). A first MACE event was experienced by 725 patients in the placebo group and 604 patients in the alirocumab group; the types and counts of total cardiovascular events and noncardiovascular deaths are presented by treatment group in Table S4. The first MACE alirocumab:placebo treatment HR (95% CI) for patients in the analysis cohort was 0.83 (0.74, 0.92), compared with 0.85 (0.78, 0.93) for the entire study population. Likewise, the corresponding results for total cardiovascular events were 0.83 (0.75, 0.92) for included patients and 0.85 (0.78, 0.93) for the entire study population.

In the placebo group, baseline IA-mass, IA-molar, and MS lipoprotein(a) concentrations had significant and nearly identical relationships with cumulative incidence of a first MACE through 4 years; spline $P=0.0001$, 0.0002 , and 0.0003 for IA-mass, IA-molar, and MS, respectively, adjusted for LDL-C, with significance essentially unchanged in sensitivity analyses featuring adjustment by additional baseline characteristics (Figure 2A). Differences in the cumulative incidence rate point estimates (adjusted for LDL-C) from the 10th to the 100th percentiles were small, differing by $\leq 0.4\%$ among the three tests (Table S5). In addition, the confidence boundaries around the splines were nearly superimposable, indicating similar population precision of the estimated lipoprotein(a)-associated risk with each of the three measurement techniques. These relationships were not modified by baseline levels of LDL-C (spline $\times$ LDL-C interaction $P>0.10$ for all three measurements). Furthermore, the alirocumab relative treatment effect was nearly identical for each of the three lipoprotein(a) assessments, with point estimates of the HRs differing by ≤ 0.07 among the tests (Table S6). There was evidence of effect modification across lipoprotein(a) IA-mass percentiles, but not IA-molar or MS percentiles (spline interaction $P=0.047$, 0.21 , and 0.16 for IA-mass, IA-molar, and MS, respectively, when adjusted for LDL-C; Figure 2B). With each test, there was nominally less risk reduction by alirocumab on a relative scale at lower lipoprotein(a) percentiles than at higher lipoprotein(a) percentiles. Corresponding findings were similar for total cardiovascular events and are presented in Figure S5, Table S5, and Table S6.

By integrated discrimination improvement analyses within the placebo group, splines of baseline IA-mass, IA-molar, and MS, both for percentiles and in original units, were incrementally prognostic for a first MACE after accounting for LDL-C (Table S7). Participants who experienced an event during follow-up had an $\approx 1.0\%$ higher expected risk of an event by 4 years compared with patients who did not have an event on the basis of baseline LDL-C concentration; this expected risk differential increased to $\approx 1.4\%$ after additionally accounting for baseline lipoprotein(a). All three lipoprotein(a) tests were significant at $P<0.05$ for incremental integrated discrimination improvement after accounting for LDL-C.

Rates of a first MACE and total cardiovascular events and absolute rate reductions with alirocumab stratified by baseline lipoprotein(a) IA-mass, IA-molar, and MS concentration quartiles are shown in Figure 3 and Figure S6. Overall, the rate of first MACE rate (95% CI) was 3.6 (3.3, 3.9) events per 100 patient-years in the alirocumab group and 4.4 (4.1, 4.7) events per 100 patient-years in the placebo group, with an absolute rate reduction (95% CI) with alirocumab of 0.8 (0.3, 1.2) events per 100 patient-years. The corresponding results for total cardiovascular events were 10.6 (10.1, 11.0), 12.8 (12.2, 13.3), and 2.2 (1.5, 2.9). Within the placebo group, the event rates increased monotonically from the lowest to the highest quartiles, with $P_{\text{trend}}<0.0001$ for all three tests for a first MACE and total cardiovascular events. Absolute rate reductions with alirocumab also generally increased from the lowest to the highest quartiles, with significant linear trends in most cases.




Figure 2: Spline analysis of risk of first MACE event by baseline lipoprotein(a) concentration percentiles. A, Cumulative incidence of first major adverse cardiovascular event (MACE) through 4 years within the placebo group. B, First MACE alirocumab:placebo hazard ratio. Splines are natural cubic with knots specified at the 25th, 50th, and 75th percentiles and reflect adjustment for baseline low-density lipoprotein cholesterol (LDL-C). Within the placebo group, spline $P=0.0001$, 0.0002 , and 0.0003 for immunoassay-based mass test (IA-mass), immunoassay-based molar test (IA-molar), and mass spectrometry (MS), respectively, adjusted for LDL-C; spline $P<0.0001$, $P<0.0001$, and $P=0.0001$ for IA-mass, IA-molar, and MS, respectively, adjusted for LDL-C, age, sex, race, body mass index, history of diabetes, and triglycerides; all spline $\times$ LDL-C interactions $P>0.10$. Treatment $\times$ spline interaction $P=0.0474$, 0.21 , and 0.16 for IA-mass, IA-molar, and MS, respectively, adjusted for LDL-C. HR indicates hazard ratio.




Figure 3: Rates of first MACE and absolute rate reductions with alirocumab stratified by baseline lipoprotein(a) IA-mass, IA-molar, and mass spectrometry concentration quartiles. Absolute risk reductions (ARRs) reflect number of first major adverse cardiovascular events (MACEs) avoided with alirocumab treatment per 100 patient-years. IA-mass indicates immunoassay-based mass test; and IA-molar, immunoassay-based molar test.

Effect of Alirocumab and Placebo on Lipoprotein(a) Concentrations

Baseline, month 4, and absolute and percentage change from baseline to month 4 in lipoprotein(a) concentration are summarized by treatment group in Table 2, overall, and by baseline quartiles. Overall, the median change in lipoprotein(a) within the alicumab group was -5.1 mg/dL, -11.9 nmol/L, and -10.4 nmol/L for IA-mass, IA-molar, and MS concentrations, respectively; overall median changes in the placebo group were minimal. The magnitude of absolute change in the alicumab group was dependent on baseline levels, in part because of fractions of patients in the lowest quartiles below or near the lower limits of quantification. In contrast, the magnitude of percent change in the alicumab group was consistently greatest in the second quartile, with somewhat lower reductions in the upper quartiles. Histograms of absolute change from baseline to month 4 for the alicumab group are presented in Figure S7.

DISCUSSION

It was previously reported from the ODYSSEY OUTCOMES trial that among patients with recent ACS who were receiving intensive or maximally tolerated statin treatment, baseline lipoprotein(a) mass measured by immunoassay was prognostic for a first MACE and total cardiovascular events. In a subset of the ODYSSEY OUTCOMES population, the current results demonstrate that in direct comparisons of mass and molar concentrations by commercial immunoassay tests, as well as molar concentration from a noncommercial MS method, all three tests were similarly prognostic for cardiovascular events within the placebo group, with higher concentrations translating to higher risk. In addition, these relationships were not modified by LDL-C levels.

Moreover, the current findings indicate numerically less relative treatment benefit of alicumab on cardiovascular events at lower lipoprotein(a) concentrations, as measured by each of the three lipoprotein(a) tests. These findings are consistent with previous findings with lipoprotein(a) measurement by IA-mass in the full trial population.^{4, 14} Baseline lipoprotein(a) concentrations by each lipoprotein(a) test were strongly and similarly predictive of absolute treatment benefits, with numerically lower absolute benefit at lower lipoprotein(a) concentrations and greater absolute benefit at higher concentrations, as determined by each lipoprotein(a) test. In sum, the current findings indicate that at the cohort level, high lipoprotein(a) concentration by each of the three measurement methods identifies high risk and an expected large absolute benefit from treatment with a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor. In addition, relative reductions of lipoprotein(a) concentration by alicumab were generally consistent across the three measurement techniques, both overall and by baseline quartile.

Although a previous study related different lipoprotein(a) measures with risk of death,²⁹ only a subset of the analysis cohort had lipoprotein(a) assessed by >1 method, and combined results

of the tests were related to outcomes. In contrast, our study applied three lipoprotein(a) tests in all patients, comprising a large, high-risk cohort, allowing for a comparison of their individual relationships with cardiovascular events. The design of the ODYSSEY OUTCOMES trial was a suitable setting to explore this issue because patients were at high risk for events resulting from a recent ACS, but the duration between the index ACS and randomization (1–12 months) minimized any acute-phase effect on lipoprotein(a) or LDL-C concentrations, as previously demonstrated by stable measurements in the placebo group at multiple time points.¹⁶ In addition, converting the units of measurements of each test to percentiles not only facilitated comparisons of three tests that comprised the current results but could provide an approach to compare some previous studies that reported on relationships between lipoprotein(a) and cardiovascular events using different assays or units of measurement.

At an individual patient level, all three measurement techniques were closely correlated. However, the relationship between baseline IA-molar and MS was nominally stronger than that for IA-mass and MS. Considering MS the gold standard method, 0.5% patients differed by at least 20 percentiles on the lipoprotein(a) distributions with IA-molar compared with 1.5% with IA-mass, implying slightly greater accuracy of IA-molar than IA-mass. In addition, Deming regression analyses indicated that the IA-molar and MS tests are not equivalent, even after accounting for the different lower limits of quantification. Whether this evidence of laboratory nonequivalence indicates a difference in clinical usefulness of IA-molar and MS is uncertain. Moreover, none of these patient-level differences translated into heterogeneity in the cohort-level relationships of IA-mass, IA-molar, and MS with cardiovascular events.

There were a priori reasons to expect greater differences among the three evaluated lipoprotein(a) tests than were identified. First, the Apo(a) component of lipoprotein(a) is heterogeneous^{19, 25} because of size polymorphism from varying numbers of kringle IV type 2 repeats and varying degrees of N- and O-glycosylation among individuals. Because of an inverse association of number of kringle IV type 2 repeats with lipoprotein(a) particle concentration, polyclonal immunoassays recognizing epitopes on Apo(a) may tend to underestimate high lipoprotein(a) concentrations and overestimate low lipoprotein(a) concentrations in the setting of small or large isoform composition, respectively.⁷ This effect is mitigated by using calibrators with varying isoforms.³⁰ Quantification of lipoprotein(a) by MS through its proteotypic peptides offers a theoretical advantage over immunoassays by directly measuring Apo(a) through its specific peptides, independent of kringle size.¹⁹ Second, there is a strong rationale to measure lipoprotein(a) in molar rather than mass concentration if the atherogenicity of lipoprotein(a) is related to particle number, rather than size. If so, one would expect greater fidelity of lipoprotein(a) molar than mass concentration to the risk of a MACE. International consensus statements support expressing lipoprotein(a) concentration in molar units.^{7, 31} However, despite all these considerations, the IA-mass, IA-molar, and MS

lipoprotein(a) tests used in this analysis performed almost indistinguishably in terms of their associations with MACE risk on a cohort level, with generally modest differences in percentile classification of individuals.

A limitation of the analyses is that the analysis cohort was a nonrandom subset of the study population, as indicated by differences in baseline characteristics between included and excluded patients. However, overall relative treatment benefits of alirocumab on a first MACE and total cardiovascular events were similar in the current analysis cohort and in the entire study population, and the relationship between lipoprotein(a) by IA-mass and cardiovascular events previously reported for the entire study population is similar to that for the current subset. Therefore, it is reasonable to expect that the current IA-molar and MS findings would extend to the full study population. In addition, comparisons of absolute differences in concentration between methods was possible for IA-molar and MS, which reported results in the same units. However, it was not possible to determine absolute differences in concentration with IA-mass versus the molar methods because of different units of measurement and because the ratio of mass and molar concentrations did not appear to be fixed, varying from 1.8 to 2.5 nmol/10 mg across. Previous studies have also compared lipoprotein(a) tests with different units of measurement using an ordinal (percentile) approach,³² and this conversion facilitates comparisons across studies.

CONCLUSIONS

In patients with recent ACS receiving high-intensity or maximum-tolerated statin treatment, two commercially available immunoassay-based tests and one MS-based test for lipoprotein(a) were similarly prognostic for a first MACE and total cardiovascular events in patients assigned to placebo and similarly predictive of reductions of these outcomes with alirocumab at the cohort level. Values of the MS-based molar test were more closely correlated with the results from the commercial immunoassay-based molar test than those from the immunoassay-based mass test, although direct comparisons of values from the two molar tests indicated that the tests were not fully equivalent. Taken together, given their similar relationships with cardiovascular events, the three tests can provide comparable clinical use in terms of information for cardiovascular risk assessment.

AFFILIATIONS

Division of Cardiology, University of Colorado School of Medicine, Aurora (M. Szarek, G.G.S.). CPC Clinical Research, Aurora, CO (M. Szarek). State University of New York, Downstate Health Sciences University, Brooklyn (M. Szarek). Departments of Clinical Chemistry and Laboratory Medicine (E.R., L.R.R., C.C.) and Cardiology (J.W.J.), Leiden University Medical Center, The

Netherlands. Netherlands Heart Institute, Utrecht (J.W.J.). Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, NY (D.L.B.). Division of Cardiovascular Disease, University of Alabama at Birmingham (V.A.B.). Estudios Cardiológicos Latino América, Instituto Cardiovascular de Rosario, Argentina (R.D.). Regeneron Pharmaceuticals Inc, Tarrytown, NY (S.F.). Sanofi, Ontario, Canada (G.G.). Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (S.G.G.). St Michael's Hospital, University of Toronto, Ontario, Canada (S.G.G.). Stanford Center for Clinical Research, Department of Medicine, Stanford University, CA (R.A.H.). Roche Diagnostics International AG, Zug, Switzerland (M. Schwertfeger). Sulpizio Cardiovascular Center, Division of Cardiovascular Medicine, University of California San Diego, La Jolla (S.T.). Green Lane Cardiovascular Research Unit, Te Whatu Ora-Health New Zealand, Te Toka Tumai, and University of Auckland, New Zealand (H.D.W.). Université ParisCité, INSERMUMR1148, Assistance PubliqueHôpitaux de Paris, Hôpital Bichat, FACT (French Alliance for Cardiovascular Trials), and Institut Universitaire de France, Paris (P.G.S.).

ACKNOWLEDGMENTS

The authors thank the patients, study coordinators, and investigators who participated in this trial. Sophie Rushton-Smith (MedLink Healthcare Communications, London, UK) provided editorial assistance in the preparation of the manuscript (limited to formatting, editing for style, referencing, and figure and table editing and submission) and was funded by Sanofi.

SOURCES OF FUNDING

This work was supported by Sanofi and Roche Diagnostics.

DISCLOSURES

Dr Szarek reports serving as a consultant or receiving research support, or both, from CiVi, Resverlogix, Lexicon, Baxter, Esperion, Amarin, NewAmsterdam, Sanofi, and Regeneron Pharmaceuticals, Inc. E. Reijnders reports no disclosures. Dr Jukema reports research grants from The Netherlands Heart Foundation, the Interuniversity Cardiology Institute of The Netherlands, and the European Commission Seventh Framework Programme, and research support from Amgen, Astellas, AstraZeneca, Daiichi-Sankyo, Lilly, Merck-Schering-Plough, Novartis, Pfizer, Roche, and Sanofi. Dr Bhatt was on advisory boards of Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, and Stasys; was on boards of directors of Angiowave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options),

High Enroll (stock), Society of Cardiovascular Patient Care, and TobeSoft; was inaugural chair of the American Heart Association quality oversight committee; was a consultant for Broadview Ventures and Hims; was on data monitoring committees of Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St Jude Medical, now Abbott), Boston Scientific (chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVIS-AGE trial, funded by Daiichi Sankyo; and for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute, and Rutgers University (for the National Institutes of Health-funded MINT Trial); received honoraria from American College of Cardiology (senior associate editor, "Clinical Trials and News," ACC.org; chair, ACC accreditation oversight committee), Arnold and Porter law firm (work related to Sanofi/Bristol Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee, funded by Boehringer Ingelheim; AEGIS-II executive committee, funded by CSL Behring), Belvoir Publications (editor-in-chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (American Heart Association lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRO-NOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor-in-chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor and associate editor), K2P (co-chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (course director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees), and Wiley (steering committee); additional disclosures: Clinical Cardiology (deputy editor), NCDR-ACTION registry steering committee (chair), and VA CART research and publications committee (chair); patent: sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital, assigned to Lexicon; Dr Bhatt nor Brigham and Women's Hospital receives any income from this patent); research funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi,

Stasys, Synaptic, The Medicines Company, Youngene, and 89Bio; royalties: Elsevier (editor, Braunwald's Heart Disease); site coinvestigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, and Vascular Solutions; trustee: American College of Cardiology; unfunded research: FlowCo and Takeda. Dr Bittner reports grant support from Sanofi, Regeneron Pharmaceuticals, Amgen, Astra Zeneca, DalCor, Esperion, and Novartis; consulting fees from Pfizer; honoraria from Medscape; and fees for participating on data safety monitoring boards for the National Institutes of Health and for Verve Therapeutics. Dr Diaz reports research grants from Sanofi, DalCor Pharmaceuticals, Population Health Research Institute, Duke Clinical Research Institute, the TIMI group, Amgen, Cirius, Montreal Health Innovations Coordinating Center, and Lepetit; and personal fees, as a member of the Executive Steering Committee, from Amgen and Cirius. Dr Fazio is an employee of Regeneron Pharmaceuticals Inc and may hold shares in the company. G. Garon is an employee of Sanofi and may hold shares in the company. Dr Goodman reports research grant support (eg, steering committee or data and safety monitoring committee) or speaker/consulting honoraria (e.g., advisory boards) from Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL, Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, and Valeo Pharma; and salary support/honoraria from the Heart and Stroke Foundation of Ontario/University of Toronto (Polo) chair, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, and the TIMI Study Group (Brigham Health). Dr Harrington reports research grants from the Patient Centered Outcomes Research Institute, National Institutes of Health, CSL, and Janssen; consulting for Atropos Health, Bitterroot Bio, Bridge Bio, Bristol Myers Squibb, Foresight, and Element Science; and served on the boards of directors for the American Heart Association (unpaid) and Cytokinetics. Dr Ruhaak reports no disclosures. Dr Schwertfeger is an employee of Roche and may hold shares in the company. Dr Tsimikas is a coinventor and receives royalties from patents owned by University of California San Diego and is a cofounder and has an equity interest in Oxitope, LLC, and its affiliates, Kleanthi Diagnostics, LLC, and has a dual appointment at the University of California San Diego and Ionis Pharmaceuticals. Dr White reports grant support paid to the institution for serving on a steering committee for the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) from Sanofi-Aventis and Regeneron Pharmaceuticals, for ACCELERATE (A Study of Evacetrapib in High-Risk Vascular Disease) from Eli Lilly and Company, for STRENGTH (Outcomes Study to Assess Statin Residual Risk Reduction With EpaNova in High CV Risk Patients With Hypertriglyceridemia) from Omthera Pharmaceuticals, for CAMELLIATIMI (A Study to Evaluate the Effect of Long-term Treatment With

BELVIQ [Lorcaserin HC] on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors) from Eisai Inc, for HEARTFID (Randomized Placebo-Controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency) from American Regent, and for ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) and the MINT Trial (Myocardial Ischemia and Transfusion) from the National Institutes of Health; received grants to the institution and personal fees as a steering committee member for the Dal-Gene study (Effect of Dalcetrapib versus Placebo on CV Risk in a Genetically Defined Population With a Recent ACS) from DalCor Pharma UK Inc, for the AEGIS-II study (The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event Reducing in Ischemic Syndromes I) from CSL Behring, for the SCORED trial (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) and the SOLOIST-WHF trial (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) from Sanofi-Aventis Australia Pty Ltd, and for the CLEAR Outcomes Study (Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid [ETC-1002] or Placebo) from Esperion Therapeutics Inc; and was on advisory boards for CSL Behring and Genentech, Inc (an affiliate of F. Hoffmann–La Roche Ltd, “Roche”; Lytics Post-PCI advisory board at European Society of Cardiology). Dr Steg reports grants, personal fees, and nonfinancial support from Sanofi; grants and personal fees from Amarin, Servier, and Bayer; and personal fees from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Idorsia, Pfizer, and Novartis. Dr Cobbaert reports research collaboration with Roche Diagnostics. Dr Schwartz reports research grants to the University of Colorado from AstraZeneca, Resverlogix, Sanofi, Silence Therapeutics, and The Medicines Company; and is coinventor of pending US patent 62/806,313 (“Methods for Reducing Cardiovascular Risk”) assigned in full to the University of Colorado.

REFERENCES

1. Nordestgaard BG and Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. *J Lipid Res.* 2016;57:1953-1975.
2. Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjaerg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS and Danesh J. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. *JAMA Cardiol.* 2018;3:619-627.
3. Lamina C and Kronenberg F. Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. *JAMA Cardiol.* 2019;4:575-579.
4. Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG, Committees OO and Investigators. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. *J Am Coll Cardiol.* 2020;75:133-144.
5. O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR and Sabatine MS. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. *Circulation.* 2019;139:1483-1492.
6. Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A and Tsimikas S. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. *Lancet.* 2018;392:1311-1320.
7. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS and Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement *Eur Heart J.* 2022;43:3925-3946.
8. Dati F, Tate JR, Marcovina SM and Steinmetz A. First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay--Lp(a) SRM 2B. *Clin Chem Lab Med.* 2004;42:670-6.
9. Tsimikas S, Moriarty PM and Stroes ES. Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. *J Am Coll Cardiol.* 2021;77:1576-1589.
10. O'Donoghue ML, JA GL, Knusel B, Gencer B, Wang H, Wu Y, Kassahun H and Sabatine MS. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoprotein(a) reduction-DOSE finding study (OCEAN(a)-DOSE). *Am Heart J.* 2022;251:61-69.
11. Ruhaak LR and Cobbaert CM. Quantifying apolipoprotein(a) in the era of proteoforms and precision medicine. *Clin Chim Acta.* 2020;511:260-268.
12. Scharnagl H, Stojakovic T, Dieplinger B, Dieplinger H, Erhart G, Kostner GM, Herrmann M, März W and Grammer TB. Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. *Atherosclerosis.* 2019;289:206-213.
13. Ruhaak LR, Romijn F, Begcevic Brkovic I, Kuklenyik Z, Dittrich J, Ceglarek U, Hoofnagle AN, Althaus H, Angles-Cano E, Coassin S, Delatour V, Deprez L, Dikaïos I, Kostner GM, Kronenberg F, Lyle A, Prinzing U, Vesper HW and Cobbaert CM. Development of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests. *Clin Chem.* 2023;69:251-261.

14. Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG and Investigators OO. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. *Eur Heart J*. 2020;41:4245-4255.
15. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A and Steg PG. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. *Am Heart J*. 2014;168:682-9.
16. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, Committees OO and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *N Engl J Med*. 2018;379:2097-2107.
17. Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG, Committees OO and Investigators. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. *J Am Coll Cardiol*. 2019;73:387-396.
18. Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD and Bhatt DL. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. *Circulation*. 2020;141:1608-1617.
19. Diederiks NM, van der Burgt YEM, Ruhaak LR and Cobbaert CM. Developing an SI-traceable Lp(a) reference measurement system: a pilgrimage to selective and accurate Apo(a) quantification. *Critical Reviews in Clinical Laboratory Sciences*. 2023;1-19.
20. van den Broek I, Romijn FP, Nouta J, van der Laarse A, Drijfhout JW, Smit NP, van der Burgt YE and Cobbaert CM. Automated Multiplex LC-MS/MS Assay for Quantifying Serum Apolipoproteins A-I, B, C-I, C-II, C-III, and E with Qualitative Apolipoprotein E Phenotyping. *Clin Chem*. 2016;62:188-97.
21. Marcovina SM and Albers JJ. Lipoprotein (a) measurements for clinical application. *J Lipid Res*. 2016;57:526-37.
22. Westgard JO. Internal quality control: planning and implementation strategies. *Ann Clin Biochem*. 2003;40:593-611.
23. Levey S and Jennings ER. The use of control charts in the clinical laboratory. *Am J Clin Pathol*. 1950;20:1059-66.
24. Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? *Atherosclerosis*. 2022;349:123-135.
25. Kronenberg F and Tsimikas S. The challenges of measuring Lp(a): A fight against Hydra? *Atherosclerosis*. 2019;289:181-183.
26. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML and Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). *Clin Chem*. 1995;41:246-55.
27. Linnet K. Evaluation of regression procedures for methods comparison studies. *Clinical chemistry*. 1993;39:424-432.
28. Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB and Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. *Statistics in Medicine*. 2008;27:157-172.

29. Langsted A, Kamstrup PR and Nordestgaard BG. High lipoprotein(a) and high risk of mortality. *Eur Heart J*. 2019;40:2760-2770.
30. Clouet-Foraison N, Vaisar T and Marcovina SM. Standardization of Analytical Methods for the Measurement of Lipoprotein(a): Bridging Past and Future Initiatives. In: K. Kostner, G. M. Kostner and P. P. Toth, eds. *Lipoprotein(a)* Cham: Springer International Publishing; 2023: 297-323.
31. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML, on behalf of the American Heart Association Council on Arteriosclerosis T, Vascular B, Council on Cardiovascular R, Intervention and Council on Peripheral Vascular D. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2022;42:e48-e60.
32. Cao J, Steffen BT, Guan W, Budoff M, Michos ED, Kizer JR, Post WS and Tsai MY. Evaluation of Lipoprotein(a) Electrophoretic and Immunoassay Methods in Discriminating Risk of Calcific Aortic Valve Disease and Incident Coronary Heart Disease: The Multi-Ethnic Study of Atherosclerosis. *Clinical chemistry*. 2017;63:1705-1713.
33. Dikaïos I, Althaus H, Angles-Cano E, Ceglarek U, Coassin S, Cobbaert CM, Delatour V, Dieplinger B, Grimmmler M, Hoofnagle AN, Kostner GM, Kronenberg F, Kuklenyik Z, Lyle AN, Prinzing U, Ruhaak LR, Scharnagl H, Vesper HW, Deprez L and on behalf of the IWgoAbMS. Commutability Assessment of Candidate Reference Materials for Lipoprotein(a) by Comparison of a MS-based Candidate Reference Measurement Procedure with Immunoassays. *Clin Chem*. 2023;69:262-272.
34. Ruhaak LR, Romijn F, Begcevic Brkovic I, Kuklenyik Z, Dittrich J, Ceglarek U, Hoofnagle AN, Althaus H, Angles-Cano E, Coassin S, Delatour V, Deprez L, Dikaïos I, Kostner GM, Kronenberg F, Lyle A, Prinzing U, Vesper HW and Cobbaert CM. Development of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests. *Clin Chem*. 2023;69:251-261.

SUPPLEMENTAL INFORMATION

Table S1: Technical Details of the Lipoprotein(a) Tests

Producer/Product name	Analyzer	Methodology	Calibration strategy	Reference material	Antibody	Analytical Measuring range	Unit	Claimed Imprecision (%)	Imprecision OOT measurements (%)
Siemens N Latex	BN II nephelometer	Nephelometry	Serial dilution from single calibrator	Internal reference material	Polyclonal	10–100 ³³	mg/dL	4.7–6.0*	3.1–4.8
Roche Tina-Quant® Lipoprotein a Gen.2	Cobas® C 502	Immunoturbidimetry	Multipoint calibration, each calibrator being independent	WHO/IFCC SRM2B	Polyclonal	7–240 ³³	nmol/L	1.2–1.7*	3.0
Lab developed multiplex MS test	Agilent 1290 Infinity II UHPLC; 6495 triple quadrupole MS	Liquid chromatography tandem mass spectrometry	Multipoint calibration, each calibrator being independent	WHO/IFCC SRM2B	–	3.8–450 ³⁴	nmol/L	7.2	3.0–3.2

* Derived from instructions for use of IVD-manufacturers. MS indicates mass spectrometry; WHO, World Health Organization; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine; UHPLC, ultra-high-performance liquid chromatography

Table S2: Demographics and Baseline Clinical Characteristics for Patients Grouped by Whether They Were Included or Excluded From the Analysis Cohort

Characteristic	Included (n=11,970)	Excluded (n=6954)	P value
Age, y	58 (52, 65)	59 (52, 65)	<0.0001
Female sex	2859 (23.9)	1903 (27.4)	<0.0001
Body mass index, kg/m ²	28.0 (25.3, 31.2)	27.8 (25.2, 30.8)	<0.0001
Systolic blood pressure, mmHg	126 (117, 138)	126 (118, 137)	0.60
Revascularization for index acute coronary syndrome	8765 (73.2)	4912 (70.6)	0.0001
Race			<0.0001
White	9622 (80.4)	5402 (77.7)	
Asian	1442 (12.0)	1056 (15.2)	
Black	325 (2.7)	148 (2.1)	
Other	581 (4.9)	348 (5.0)	
Region of enrollment			<0.0001
Central and Eastern Europe	2318 (19.4)	3119 (44.9)	
Western Europe	2820 (23.6)	1355 (19.5)	
Canada or United States	2814 (23.5)	57 (0.8)	
Latin America	1594 (13.3)	994 (14.3)	
Asia	1381 (11.5)	92 (13.1)	
Rest of World	1043 (8.7)	517 (7.4)	
Baseline laboratory data			
Lipoprotein(a) immunoassay-based mass concentration, mg/dL	21.8 (6.9, 60.0)	20.1 (6.4, 58.6)	0.0170
Lipoprotein(a) immunoassay-based molar concentration, nmol/L	45.0 (13.2, 153.8)	n/a	n/a
Lipoprotein(a) mass spectrometry-based concentration, nmol/L	42.2 (14.3, 143.1)	n/a	n/a
Low-density lipoprotein cholesterol, mg/dL	86.5 (73.0, 104.2)	86.1 (73.0, 103.5)	0.84
Corrected Low-density lipoprotein cholesterol, mg/dL	75.3 (60.6, 93.8)	75.6 (60.7, 93.3)	0.96
Apolipoprotein B, mg/dL	80.0 (69.0, 94.0)	78.0 (68.0, 91.0)	<0.0001
Non-high-density lipoprotein cholesterol, mg/dL	115.1 (99.0, 137.5)	114.0 (99.2, 135.5)	0.0345
High-density lipoprotein cholesterol, mg/dL	42.1 (36.0, 50.0)	43.0 (37.1, 51.0)	<0.0001
Triglycerides, mg/dL	131.0 (94.7, 184.0)	128.0 (93.8, 177.0)	0.0010
High Sensitivity C-reactive Protein, mg/dL	0.17 (0.08, 0.39)	0.17 (0.08, 0.35)	0.0329
Estimated glomerular filtration rate, mL/min/1.73 m ²	78.2 (67.2, 90.4)	78.2 (67.6, 90.1)	0.53
Hemoglobin A1c, %	5.8 (5.5, 6.3)	5.8 (5.5, 6.3)	0.12
Medical history before index ACS			
Hypertension	7546 (63.0)	4703 (67.6)	<0.0001
Diabetes mellitus	3536 (29.5)	1908 (27.4)	0.0021
Current tobacco smoker	2893 (24.2)	1667 (24.0)	0.76
Myocardial infarction	2321 (19.4)	1318 (19.0)	0.46
Percutaneous coronary intervention	2254 (18.8)	987 (14.2)	<0.0001
Coronary artery bypass grafting	730 (6.1)	317 (4.6)	<0.0001
Stroke	375 (3.1)	236 (3.4)	0.33
Peripheral artery disease	491 (4.1)	268 (3.9)	0.40
Congestive heart failure	1111 (9.3)	1704 (24.5)	<0.0001
Chronic obstructive pulmonary disease	535 (4.5)	211 (3.0)	<0.0001
Malignancy	413 (3.5)	119 (1.7)	<0.0001
Time from index ACS to randomization, months	2.7 (1.7, 4.5)	2.6 (1.7, 4.0)	<0.0001

Characteristic	Included (n=11,970)	Excluded (n=6954)	P value
Background lipid lowering therapy at randomization			<0.0001
High-dose atorvastatin/rosuvastatin	10,647 (88.9)	6164 (88.6)	
Low- or moderate-dose atorvastatin/rosuvastatin	900 (7.5)	707 (10.2)	
No statin or other lipid-lowering therapy	153 (1.3)	25 (0.4)	
Only lipid-lowering therapy other than statin	234 (2.0)	48 (0.7)	
Other statin	36 (0.3)	10 (0.1)	
Randomized to alirocumab	5977 (49.9)	3485 (50.1)	0.81

Values are medians (interquartile range) for continuous variables and n (%) for categorical variables.

Table S3: Spearman Correlations for Baseline Lipoprotein(a) Concentrations and LDL-C for the Overall Analysis Cohort

	IA-mass	IA-molar	MS	LDL-C	LDL-C _{corr}
IA-mass	1	0.972	0.967	0.134	-0.309
IA-molar	0.972	1	0.990	0.135	-0.296
MS	0.967	0.990	1	0.128	-0.299
LDL-C	0.134	0.135	0.128	1	0.854

*LDL-C = 0.3 x IA-mass.

IA indicates immunoassay; LDL-C, low-density lipoprotein cholesterol; MS, mass spectrometry.

Table S4: Categories and Counts of Total Events for the Analysis Cohort

Event	Alirocumab (n = 5977)	Placebo (n = 5993)	Total (n = 11,970)
Cardiovascular	1856	2242	4098
Coronary heart disease death	147	175	322
Non-fatal myocardial infarction	596	721	1317
Ischemia-driven coronary revascularization	622	712	1334
Non-fatal heart failure requiring hospitalization	214	225	439
Unstable angina requiring hospitalization	26	47	73
Death related to underlying coronary heart disease ^a	2	8	10
Ischemic stroke	83	113	196
Fatal	6	9	15
Non-fatal	77	104	181
Hemorrhagic stroke	11	7	18
Fatal	5	1	6
Non-fatal	6	6	12
Death related to peripheral disease	6	7	13
Peripheral artery disease ^b	116	172	288
Limb revascularization ^b	81	119	200
Critical limb ischemia ^b	35	53	88
Venous thromboembolism event ^b	33	55	88
Deep venous thrombosis ^b	18	29	47
Pulmonary embolism ^b	15	26	41
Non-cardiovascular death	62	85	147

Values are n.

^aHeart failure, cardiogenic shock, cardiovascular procedure, cardiovascular hemorrhage.

^bInvestigator reported; not subject to adjudication by independent committee.

Table S5: Estimated Cumulative Incidence of First MACE and Total CV Events per 100 Patients Through 4 Years at Landmark Lipoprotein(a) Percentiles from Spline Analysis Within the Placebo Group

Estimated Cumulative Incidence (95% CI)			
Lipoprotein(a) Percentile	IA-mass	IA-molar	MS
10th	13.1% (11.1–15.5)	13.5% (11.4–15.9)	13.5% (11.5–15.9)
25th	14.4% (12.9–16.0)	14.5% (13.0–16.1)	14.5% (13.1–16.2)
50th	16.7% (14.8–19.0)	16.3% (14.4–18.5)	16.4% (14.5–18.6)
75th	19.0% (17.3–20.9)	18.9% (17.1–20.7)	18.8% (17.1–20.7)
90th	20.5% (17.9–23.4)	20.6% (18.0–23.6)	20.4% (17.8–23.3)
100th	21.5% (17.9–25.8)	21.9% (18.3–26.2)	21.5% (18.0–25.8)
Estimated Total CV Events per 100 Patients (95% CI)			
Lipoprotein(a) Percentile	IA-mass	IA-molar	MS
10th	40.7 (37.2–44.6)	42.1 (38.5–46.1)	42.7 (39.0–46.7)
25th	42.6 (40.1–45.2)	42.6 (40.1–45.2)	43.1 (40.6–45.7)
50th	46.4 (43.2–49.9)	44.7 (41.6–48.1)	45.0 (41.8–48.4)
75th	53.5 (50.7–56.5)	53.0 (50.2–55.9)	52.6 (49.8–55.5)
90th	58.8 (54.4–63.5)	59.8 (55.4–64.5)	58.8 (54.5–63.4)
100th	62.6 (56.4–69.4)	64.8 (58.5–71.1)	63.3 (57.2–70.1)

Rates reflect adjustment for LDL-C. CV indicates cardiovascular; IA, immunoassay; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event; MS, mass spectrometry

Table S6: Estimated Treatment Hazard Ratios for First MACE and Total CV Events at Landmark Lipoprotein(a) Percentiles from Spline Analysis

Estimated First MACE Treatment HR (95% CI)			
Lipoprotein(a) Percentile	IA-mass	IA-molar	MS
10th	1.07 (0.85–1.35)	1.00 (0.79–1.26)	1.01 (0.80–1.27)
25th	0.90 (0.78–1.05)	0.90 (0.77–1.04)	0.89 (0.76–1.03)
50th	0.73 (0.60–0.88)	0.77 (0.64–0.93)	0.75 (0.62–0.90)
75th	0.76 (0.66–0.87)	0.77 (0.67–0.88)	0.77 (0.68–0.89)
90th	0.81 (0.66–0.99)	0.79 (0.65–0.96)	0.81 (0.67–0.99)
100th	0.84 (0.64–1.11)	0.80 (0.61–1.04)	0.85 (0.65–1.10)
Estimated Total CV Events Treatment HR (95% CI)			
Lipoprotein(a) Percentile	IA-mass	IA-molar	MS
10th	0.99 (0.79–1.24)	0.93 (0.75–1.17)	0.94 (0.75–1.17)
25th	0.89 (0.77–1.03)	0.88 (0.77–1.02)	0.88 (0.76–1.01)
50th	0.77 (0.64–0.93)	0.82 (0.68–0.98)	0.80 (0.66–0.97)
75th	0.78 (0.68–0.90)	0.79 (0.69–0.91)	0.80 (0.69–0.91)
90th	0.81 (0.66–1.00)	0.78 (0.64–0.96)	0.80 (0.65–0.99)
100th	0.83 (0.63–1.09)	0.78 (0.59–1.02)	0.81 (0.61–1.07)

Rates reflect adjustment for LDL-C. CV indicates cardiovascular; HR, hazard ratio; IA, immunoassay; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event; MS, mass spectrometry

Table S7: Integrated Discrimination Improvement for Splines of Baseline IA-Mass, IA-Molar, and MS as Percentiles and in Original Units When Added to Models with LDL-C Within the Placebo Group and first MACE as the Outcome

Model	Mean estimated risk for first mace through 4 years, %, among patients:		Integrated discrimination improvement, %		
	With MACE (n=725)	Without MACE (n=5268)	Absolute	Relative	P value
LDL-C	18.6	17.6	n/a	n/a	n/a
LDL-C + IA-mass percentile	19.0	17.6	0.4	40.3	0.0007
LDL-C + IA-molar percentile	19.0	17.6	0.4	39.8	0.0007
LDL-C + MS percentile	18.9	17.6	0.4	36.7	0.0011
LDL-C + IA-mass	19.0	17.6	0.4	42.2	0.0006
LDL-C + IA-molar	19.0	17.6	0.4	40.9	0.0007
LDL-C + MS	18.9	17.6	0.2	23.6	0.0292

* LDL-C – 0.3 x IA-mass

IA indicates immunoassay; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event; MS, mass spectrometry; n/a, not available.




Figure S1: Histogram of baseline lipoprotein(a) concentrations for all patients in the analysis cohort: (A) Immunoassay-based mass concentration; (B) Immunoassay-based molar concentration; (C) Mass spectrometry molar concentration. Median (IQR) overall baseline concentrations were 21.8 (6.9, 60.0) mg/dL for IA-mass, 45.0 (13.2, 153.8) nmol/L for IA-molar, and 42.2 (14.3, 143.1) nmol/L for MS. IA indicates immunoassay.




Figure S2: Scatterplots of baseline IA-mass lipoprotein(a) concentration by (A) the ratio of IA-molar to IA-mass lipoprotein(a) concentrations and (B) the ratio of MS to IA-mass lipoprotein(a) concentrations. Plots include 9990 patients who were above the lower limits of quantification on all three tests. Solid lines within plot are LOWESS curves utilizing 20 observations within the smoothing windows. Dashed horizontal lines designate a ratio of 2.5. IA indicates immunoassay; MS, mass spectrometry.




Figure S3: Bland-Altman analysis of baseline lipoprotein(a) IA-molar vs. MS concentrations. Overall bias was 3.8 nmol/L, with 95% limits of agreement of -50.7 to 58.3 nmol/L.




Figure S4: Deming regression analysis of baseline lipoprotein(a) IA-molar vs. MS concentrations. With MS specified as the predictor variable and IA-molar specified as the outcome, the estimated slope (95% confidence interval [CI]) is 1.03 (1.02, 1.04) and the estimated y-intercept is 1.07 (0.37, 1.78). The solid line within the plot reflects the estimated slope and y-intercept. Excluding participants below the lower limit of quantification on the MS test, the estimated slope (95% CI) is 1.03 (1.02, 1.04) and the estimated y-intercept is 1.01 (0.23, 1.79). Excluding participants below the lower limit of quantification on either test, the estimated slope (95% CI) is 1.03 (1.01, 1.04) and the estimated y-intercept is 1.72 (0.82, 2.63). IA indicates immunoassay; MS, mass spectrometry.




Figure S5: Spline analysis of total cardiovascular events by baseline lipoprotein(a) concentration percentiles: (A) Total cardiovascular events per 100 patients through 4 years within the placebo group; (B) total cardiovascular events alirocumab:placebo hazard ratio. Splines are natural cubic with knots specified at the 25th, 50th, and 75th percentiles and reflect adjustment for baseline LDL-C_{corr}. All spline $P < 0.0001$ adjusted for LDL-C_{corr} and spline $P = 0.0007$, 0.0003, and 0.0011 for IA-mass, IA-molar, and MS, respectively adjusted for LDL-C within the placebo group. All spline $\times$ LDL-C_{corr} and spline $\times$ LDL-C interaction $P > 0.10$ within the placebo group. All treatment $\times$ spline interaction $P > 0.10$ adjusted for LDL-C_{corr} and $P > 0.10$ adjusted for LDL-C. CI indicates confidence interval; CV, cardiovascular; IA, immunoassay; LDL-C, low-density lipoprotein cholesterol; LDL-C_{corr}, corrected low-density lipoprotein cholesterol; MS, mass spectrometry; HR, hazard ratio.




Figure S6: Rates of total cardiovascular events and absolute rate reductions with alirocumab stratified by baseline lipoprotein(a) IA-mass, IA-molar, and MS concentration quartiles. ARR reflects total number of cardiovascular events avoided with alirocumab treatment per 100 patient-years. ARR indicates absolute risk reduction; CI, confidence interval; IA, immunoassay; MS, mass spectrometry.




Figure S7: Histogram of absolute change in lipoprotein(a) concentrations from baseline to month 4 in the alirocumab group: (A) IA-mass; (B) IA-molar; and (C) MS. Median (IQR) absolute change in concentrations from baseline to month 4 within the alirocumab group were -5.1, (-13.4, 0) mg/dL for IA-mass, -11.9 (-32.0, -2.0) nmol/L for IA-molar, and -10.4 (-28.2, -2.7) nmol/L for MS. IA indicates immunoassay; MS, mass spectrometry.